DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)

Information source: Ludwig-Maximilians - University of Munich
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Mellitus, Type 2

Intervention: exendin(9-39)amide (Drug); saline (Drug); duodenal meal (Other); duodenal saline (Other)

Phase: Phase 1

Status: Completed

Sponsored by: Ludwig-Maximilians - University of Munich

Official(s) and/or principal investigator(s):
Joerg Schirra, MD, Principal Investigator, Affiliation: Clinical Research Unit (CRU), Department of Internal Medicine, Campus Großhadern, Clinical Center of Ludwig-Maximilians-University of Munich


The purpose of the study is to determine the contribution of endogenous Glucagon-like peptide 1 (GLP-1) to the postprandial secretion of insulin and glucagon and the incretin effect in healthy subjects and patients with type 2 diabetes mellitus (T2DM).

Clinical Details

Official title: The Contribution of Glucagon-like Peptide 1 (GLP-1) to the Entero-insulinar Axis in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Primary outcome: The incretin effect

Secondary outcome:

Plasma concentrations of glucagon

Plasma concentrations of insulin

Plasma concentrations of C-peptide

Plasma concentrations of Glucagon-like peptide-1(7-36) (GLP-1(7-36))

Plasma concentrations of Glucose-dependent insulinotropic polpypeptide (GIP)


Minimum age: 30 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria:

- male or female (postmenopausal, surgically sterile or using double-barrier method of

contraception) healthy subjects and patients with type 2 diabetes mellitus (T2DM)

- must be able to complete a 1 week wash-out of current anti-diabetic medications

- Age 30-70 years

- HbA1c (Hemoglobin A1c) ≤11% at screening

- Body mass index (BMI) <40 kg/m2

- Patients with type 2 diabetes mellitus (T2DM): Must have a fasting blood glucose of

≤12. 2 mmol/L (240 mg/dL) at screening

- Able to provide written informed consent prior to study participation

- Able to communicate well with the investigator and comply with the requirements of

the study Exclusion Criteria:

- Patients with type 1 diabetes mellitus (T1DM), diabetes as a result of pancreatic

injury, or secondary forms of diabetes (eg Cushing, acromegaly)

- Need for insulin within the previous 3 months

- Use of Thiazolidinediones in the previous 4 weeks

- Significant concomitant disease or complications of diabetes (i. e. nephropathy,

autonomic dysfunction, orthostasis).

- Treatment with systemic steroids and thyroid hormone (unstable dosage).

- Patients with any history of gastrointestinal surgery, e. g. partial bowel resections,

partial gastric resections, etc.

- Participation in any clinical investigation within 4 weeks prior to dosing or longer

if required by local regulation.

- Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.

- Significant illness within the two weeks prior to dosing.

- Past medical history of clinically significant ECG abnormalities or a family history

of a prolonged QT-interval syndrome.

- History of clinically significant drug allergy; history of atopic allergy (asthma,

urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug.

- history of major gastrointestinal tract surgery such as gastrectomy,

gastroenterostomy, or bowel resection;

- history or clinical evidence of pancreatic injury or pancreatitis;

- history or presence of impaired renal function as indicated by abnormal creatinine or

urea val-ues or abnormal urinary constituents (e. g., albuminuria);

- evidence of urinary obstruction or difficulty in voiding at screening;

- Polymorphonuclears <1500/µL at inclusion or platelet count < 100,000/μL at screening

and baseline.

- History of immunocompromise.

- Evidence of liver disease as indicated by abnormal transaminases and alkaline

phosphatase exceeding twice the upper limit of the normal range, and serum bilirubin should not exceed the value of 27 µmol/L (1. 6 mg/dL).

Locations and Contacts

Clinical Research unit, Dept. of Internal Medicine II - Großhadern, University of Munich, Munich 81377, Germany

Ludwig Maximilians-University, Clinical Research Unit, Munich 80999, Germany

Additional Information

Starting date: December 2006
Last updated: October 5, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017